

Comprehensive Analysis of Thalassemia Alleles

Introduction


Thalassemia is a group of inherited hemolytic disorders characterized by reduced or absent production of globin chains, involving a spectrum of globin gene defects. This genetic complexity significantly limits the detection coverage of routine molecular assays, creating blind spots in comprehensive variant profiling. These limitations can lead to increased turnaround times, higher costs, and added burdens in clinical aspects.

Now, with advances in long-read sequencing (LRS) technologies, it is possible to offer an all-in-one assay capable of detecting a broad spectrum of variants in a cost-effective manner — Comprehensive Analysis of Thalassemia Alleles (CATSA).

CATSA - LRS Application Built for Commercial Scale

Developed by Berry Genomics, CATSA is a targeted LRS panel specifically designed to streamline the detection of thalassemia variants into a single, standardized assay. Optimized for large-scale applications, it includes a set of reagents and integrated software, enabling a seamless workflow from sample management to variant reporting.

IVD certificated solution
350,000 cases | 50+ publications




Prospective Multi-Center Study

A total of 1,759 blood samples with abnormal hemoglobin parameters were collected across 10 centers to compare CATSA with a standard PCR panel. All CATSA-detected pathogenic variants were further confirmed.

Highlighted Findings:

- CATSA detected pathogenic thalassemia variants in 1,159 samples (65.9%), identifying 1,317 variants
- CATSA demonstrated 100% accuracy in detection
- PCR assays produced 2 false negatives and 7 false positives within its panel
- HBA1/HBA2 structural variants in 10 samples were missed or misclassified as α -^{3,7} by PCR assays



Information derived from reference [2]

Streamline detection with CASTA

CATSA All-in-one assay

- α -thalassemia**
 - 30 Deletions
 - 5 Homologous recombination
 - 80 HBA1 gene mutations
 - 139 HBA2 gene mutations
- β -thalassemia**
 - 28 Deletions
 - 340 HBB gene mutations
- Hemoglobinopathy**
 - 324 HBA1 gene mutations
 - 386 HBA2 gene mutations
 - 694 HBB gene mutations
- Others**
 - 160 HBD gene mutations
 - HBA1/2 and HBB variants that are low-frequency, not clearly associated with thalassemia or hemoglobin abnormalities

Complete blood count + Hemoglobin electrophoresis

Some carriers (e.g., α / β -thalassemia, α -tripleuplications) may be missed

| Sequential hematological screening MCV + MCH and HbA2 | | |
|---|-------------|-------------|
| | Sensitivity | Specificity |
| α -thalassemia | 16.53% | 97.24% |
| β -thalassemia | 73.74% | 96.10% |

Compare with NGS panel in China Dai nationality. Information derived from reference [1]

PCR-based assays

Missing carriers with rare deletions, homologous recombination, and uncommon SNVs/InDels

| Routine PCR panel in China for common variants | |
|--|--|
| HBA1/ HBA2 | 3 Deletions: --SEA, - α ^{3,7} , - α ^{4,2} 3 SNVs: Hb Westmead, Hb Quong Sze, Hb Constant Spring |
| HBB | 17 SNVs/InDels: -32, -30, -29, -28, Initiation codon, Cap+1, Codon 17, Codon 14/15, HbE, Codon 27/28, Codon 31, Codon 43, Codon 41/42, Codon 71/72, IVS-1-1, IVS-1-5, IVS-II-654 |

Next-generation sequencing (NGS)

The limitations of short-read sequencing may lead to inaccurate detection of large deletions and recombination, and often fail to resolve the cis/trans configuration of variants.

Comparison Between CATSA and NGS

NGS and CATSA were simultaneously performed for 1,122 individuals in Hainan Province. All discordant variants were subsequently confirmed.

Highlighted Findings:

- 1,105 samples (98.48%) showed concordant results between CATSA and NGS, while 17 samples (1.52%) had discordant results
- CATSA improved the positive detection rate by 2.28%

| NGS | | CATSA | |
|---|---------------|---|---------------|
| HBA Variants | HBB Variants | HBA Variants | HBB Variants |
| α - ^{3,7} /+ | ND | HK α / α | ND |
| ND | ND | HBA2:c.369C>G Hete | ND |
| ND | ND | -- α ^{3,7} / α | ND |
| ND | c.126_129del | ND | c.126_129del |
| ND | CTTT Homo | α α ^{4,2} / α | CTTT Hete |
| ND | c.126_129del | α α ^{4,2} / α | c.126_129del |
| ND | CTTT Hete | ND | CTTT Hete |
| -- α ^{3,7} /HK α (?) | ND | -- α ^{3,7} /HK α | ND |
| ND | c.341T>A Hete | α α ^{4,2} / α | c.341T>A Hete |
| α Fusion/ α Fusion | ND | α Fusion/ α | ND |
| ND | ND | α α ^{4,2} / α | ND |
| HBA2:c.*98T>C Hete | ND | α α ^{4,2} /HBA2:c.*98T>C | ND |
| ND | ND | α α ^{4,2} / α | ND |
| ND | ND | α α ^{4,2} / α | ND |
| ND | ND | α α ^{4,2} / α | ND |
| ND | ND | α α ^{4,2} / α | ND |

Discordant Results Between CATSA and NGS

Information derived from reference [3]

A total of 2,926 participants were retrospectively enrolled in Shanghai for carrier screening of 5 diseases using both NGS and LRS panels, with CATSA applied for thalassemia.

Highlighted Findings:

- LRS detected 16 α ⁰ variants, 47 α ⁺ variants, and 50 α -tripleuplications /quadruplications
- NGS failed to identify all α -tripleuplications and misclassified 10 HK α variants as α -^{3,7}, resulting in an error rate of 13.7% (10/73) among α -thalassemia positive samples

| Gene | Variant | Carriers of the variant | | Carriers of the gene | |
|--------------|--|-------------------------|-----------------|----------------------|-----------------|
| | | LRS | NGS | LRS | NGS |
| HBA1, HBA2 | HBA2:c.342delC (α ⁺) | 1 | 1 | 63 | 63 |
| | HBA2:c.369C>G (α ⁺) | 1 | 1 | | |
| | HBA2:c.427T>C (α ⁺) | 1 | 1 | | |
| | --SEA (α ⁺) | 15 | 15 | | |
| | -- α ^{3,7} (α ⁺) | 1 | 1 | | |
| | - α ^{3,7} (α ⁺) | 1 | 1 | | |
| | - α ^{4,2} (α ⁺) | 37 | 37 | | |
| | - α ^{4,2} (α ⁺) | 6 | 6 | | |
| | False positive - α ^{3,7} | 0 | 10 ^B | 0 | 10 ^B |
| | α α ^{4,2} | 29 | 0 | 50 | 0 |
| | α α ^{4,2} | 20 | 0 | | |
| HBB | α α ^{4,2} | 1 | 0 | | |
| | c.-78A>G | 2 | 2 | 19 | 19 |
| | c.17_18delCT | 1 | 1 | | |
| | c.52A>T | 2 | 2 | | |
| | c.79G>A | 2 | 2 | | |
| | c.92+5G>C | 1 | 1 | | |
| | c.126_129delCTTT | 5 | 5 | | |
| c.316-197C>T | 6 | 6 | | | |

Thalassemia carriers identified by LRS and NGS panels

Information derived from reference [4]

Potential Impacts on Prenatal Aspects

A total of 278 amniotic fluid samples from at-risk pregnancies were collected across 9 hospitals. PCR-based methods were used for prenatal diagnosis, while CATSA was performed retrospectively and blindly on all samples. All inconsistent results underwent variant confirmation.

Highlighted Findings:

- CATSA corrected the results in 15 samples (5.4%) with 100% accuracy: 4 within the PCR panel, 4 outside the panel, and 7 classified as variants of uncertain significance
- 8 of them had revised phenotype prediction, including 2 reclassified from β -thalassemia trait to intermedia, and 1 from β -thalassemia major to trait

Information derived from reference [5]

Xcelom Limited
Subsidiary of Berry Genomics

Email: marketing@xcelom.com



LinkedIn



Website (Global)

References: [1] He J, Song W, Yang J, et al. Next-generation sequencing improves thalassemia carrier screening among premarital adults in a high prevalence population: the Dai nationality, China. *Genet Med*. 2017;19(9):1022-1031. [2] Liang Q, Gu W, Chen P, et al. A More Universal Approach to Comprehensive Analysis of Thalassemia Alleles (CATSA). *J Mol Diagn*. 2021;23(9):1195-1204. [3] Huang R, Liu Y, Xu J, et al. Back-to-Back Comparison of Third-Generation Sequencing and Next-Generation Sequencing in Carrier Screening of Thalassemia. *Arch Pathol Lab Med*. 2024;148(7):797-804. [4] Li S, Hua R, Han X, et al. Targeted long-read sequencing facilitates effective carrier screening for complex monogenic diseases including spinal muscular atrophy, α / β -thalassemia, 21-hydroxylase deficiency, and fragile-X syndrome. *J Transl Med*. 2025;23(1):307. [5] Liang Q, He J, Li Q, et al. Evaluating the Clinical Utility of a Long-Read Sequencing-Based Approach in Prenatal Diagnosis of Thalassemia. *Clin Chem*. 2023;69(3):239-250.

INT_TGSthalav1.4012026 © 2026 Xcelom Limited. All rights reserved. Information in this document is subject to change without notice. Information provided is intended for reference only. All trademarks are the property of Berry Genomics, or their respective owners.